Evidence map›Paper›PMID 37845689›Full record

ArticleGenome medicine2023

Single-cell RNA sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia.

Hope L Mumme, Sunil S Raikar, Swati S Bhasin, Beena E Thomas, Taylor Lawrence, Elizabeth P Weinzierl, Yakun Pang, Deborah DeRyckere, Chuck Gawad, Daniel S Wechsler and 4 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Downregulation ofBalkan medical journal · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Frontiers in oncology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Hope L Mumme *Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Sunil S Raikar *Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Swati S BhasinAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Beena E ThomasAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Taylor LawrenceAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Elizabeth P WeinzierlDepartment of Pathology and Laboratory Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA.
Yakun PangDepartment: Pediatrics - Hematology/Oncology, Stanford University, Stanford, CA, USA.
Deborah DeRyckereAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Chuck GawadDepartment: Pediatrics - Hematology/Oncology, Stanford University, Stanford, CA, USA.
Daniel S WechslerAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Christopher C PorterAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Sharon M CastellinoAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Douglas K GrahamAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
Manoj BhasinAflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA. manoj.bhasin@emory.edu.
Aflac (United States) · USChildren's Healthcare of Atlanta · USStanford University · USEmory University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMixed phenotype acute leukemia (MPAL), a rare subgroup of leukemia characterized by blast cells with myeloid and lymphoid lineage features, is difficult to diagnose and treat. A better characterization of MPAL is essential to understand the subtype heterogeneity and how it compares with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Therefore, we performed single-cell RNA sequencing (scRNAseq) on pediatric MPAL bone marrow (BM) samples to develop a granular map of the MPAL blasts and microenvironment landscape.

methodsWe analyzed over 40,000 cells from nine pediatric MPAL BM samples to generate a single-cell transcriptomic landscape of B/myeloid (B/My) and T/myeloid (T/My) MPAL. Cells were clustered using unsupervised single-cell methods, and malignant blast and immune clusters were annotated. Differential expression analysis was performed to identify B/My and T/My MPAL blast-specific signatures by comparing transcriptome profiles of MPAL with normal BM, AML, and ALL. Gene set enrichment analysis (GSEA) was performed, and significantly enriched pathways were compared in MPAL subtypes.

resultsB/My and T/My MPAL blasts displayed distinct blast signatures. Transcriptomic analysis revealed that B/My MPAL profile overlaps with B-ALL and AML samples. Similarly, T/My MPAL exhibited overlap with T-ALL and AML samples. Genes overexpressed in both MPAL subtypes' blast cells compared to AML, ALL, and healthy BM included MAP2K2 and CD81. Subtype-specific genes included HBEGF for B/My and PTEN for T/My. These marker sets segregated bulk RNA-seq AML, ALL, and MPAL samples based on expression profiles. Analysis comparing T/My MPAL to ETP, near-ETP, and non-ETP T-ALL, showed that T/My MPAL had greater overlap with ETP-ALL cases. Comparisons among MPAL subtypes between adult and pediatric samples showed analogous transcriptomic landscapes of corresponding subtypes. Transcriptomic differences were observed in the MPAL samples based on response to induction chemotherapy, including selective upregulation of the IL-16 pathway in relapsed samples.

conclusionsWe have for the first time described the single-cell transcriptomic landscape of pediatric MPAL and demonstrated that B/My and T/My MPAL have distinct scRNAseq profiles from each other, AML, and ALL. Differences in transcriptomic profiles were seen based on response to therapy, but larger studies will be needed to validate these findings.

Indexed as

Leukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAcute DiseaseAdultChildHumansPhenotypeSequence Analysis, RNATumor MicroenvironmentMixed phenotype acute leukemiaSingle-cell RNA sequencingTumor microenvironment

Identifiers

PMID37845689
PMCPMC10577904
OpenAlexW4387668926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.